ArticleVaccines2021
COVID-19 Vaccination Scenarios: A Cost-Effectiveness Analysis for Turkey.
Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Predictive models for health outcomes due to SARS-CoV-2, including the effect of vaccination: a systematic review.Systematic reviews · 2024Pooled it
- Economic evaluation of COVID-19 vaccination: A systematic review.Journal of global health · 2023Pooled it
- Cost-effectiveness of interventions for the prevention and control of COVID-19: Systematic review of 85 modelling studies.Journal of global health · 2022Pooled it
- Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies.Frontiers in public health · 2022Pooled it
- Paid and unpaid productivity losses across 28 European countries due to excess deaths and COVID-19 deaths from 2020 to 2023.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Assessing the Economic Benefit of Mass COVID-19 Vaccination Program in Iran: A Real-World Modeling Study.International journal of health policy and management · 2025Article
- Article
- Article
- Cost-Effectiveness Analysis of Vaccines for COVID-19 According to Sex, Comorbidity and Socioeconomic Status: A Population Study.PharmacoEconomics · 2024Article
- Pharmacy practice and policy research in Türkiye: a systematic review of literature.Journal of pharmaceutical policy and practice · 2024Review
- Assessing the cost-effectiveness of COVID-19 vaccines in a low incidence and low mortality setting: the case of Thailand at start of the pandemic.The European journal of health economics : HEPAC : health economics in prevention and care · 2023Article
- COVID-19 and Vaccination Status in Lysosomal Storage Diseases: A Single-Center Experience.Turkish archives of pediatrics · 2023Article
- Cost-effectiveness of COVID-19 vaccination in Latin America and the Caribbean: an analysis in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and Peru.Cost effectiveness and resource allocation : C/E · 2023Article
- Economic evaluation of strategies against coronavirus: a systematic review.Health economics review · 2023Review
- Review
- Assessment of drugs administered in the Middle East as part of the COVID-19 management protocols.Inflammopharmacology · 2022Review
- Cost-Effectiveness of COVID-19 Sequential Vaccination Strategies in Inactivated Vaccinated Individuals in China.Vaccines · 2022Article
- Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya.BMJ global health · 2022Article
- Anti-Biofilm and Antibacterial Activities ofAntibiotics (Basel, Switzerland) · 2022Article
- Value-based pricing of a COVID-19 vaccine.The Quarterly review of economics and finance : journal of the Midwest Economics Association · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As of March 2021, COVID-19 has claimed the lives of more than 2.7 million people worldwide. Vaccination has started in most countries around the world. In this study, we estimated the cost-effectiveness of strategies for COVID-19 vaccination for Turkey compared to a baseline in the absence of vaccination and imposed measures by using an enhanced SIRD (Susceptible, Infectious, Recovered, Death) model and various scenarios for the first year after vaccination. The results showed that vaccination is cost-effective from a health care perspective, with an incremental cost-effectiveness ratio (ICER) of 511 USD/QALY and 1045 USD/QALY if vaccine effectiveness on transmission is equal or reduced to only 50% of effectiveness on disease, respectively, at the 90% baseline effectiveness of the vaccine. From a societal perspective, cost savings were estimated for both scenarios. Other results further showed that the minimum required vaccine uptake to be cost-effective would be at least 30%. Sensitivity and scenario analyses, as well as the iso-ICER curves, showed that the results were quite robust and that major changes in cost-effectiveness outcomes cannot be expected. We can conclude that COVID-19 vaccination in Turkey is highly cost-effective or even cost-saving.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.